Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.645 EUR | +4.93% | +4.54% | -14.98% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.98% | 270M | |
-0.02% | 42.11B | |
+48.26% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix Enrolls First Patient in Phase 3 Study of Head, Neck Cancer Treatment